Study Preview
Study Title and Description
Acute caffeine ingestion enhances strength performance and reduces perceived exertion and muscle pain perception during resistance exercise.
Key Questions Addressed
1 | For [population], is caffeine intake above [exposure dose], compared to intakes [exposure dose] or less, associated with adverse effects on cardiovascular outcomes? |
Primary Publication Information
Title | Acute caffeine ingestion enhances strength performance and reduces perceived exertion and muscle pain perception during resistance exercise. |
Author | MJ Duncan,M Stanley,N Parkhouse,K Cook,M Smith, |
Country | |
Year | 2013 |
Numbers |
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Cardiovascular Design
Question... Follow Up | Answer | Follow-up Answer | |
---|---|---|---|
What outcome is being evaluated in this paper? | Cardiovascular | ||
What is the objective of the study (as reported by the authors)? | The aim of this study was to examine the effect of acute caffeine ingestion on resistance exercise to failure post-exercise muscle pain and perceived exertion in the bench press, deadlift, prone row and back squat. It was hypothesized that, compared to placebo, caffeine will significantly improve repetitions to failure whilst reducing ratings of perceived exertion and muscle pain. | ||
Provide a general description of the methods as reported by the authors. Information should be extracted based on relevance to the SR (i.e., caffeine related methods) | Subjects: All participants were asked to refrain from vigorous exercise and maintain normal dietary patterns in the 48 hours prior to testing and were asked not to consume caffeine after 6:00 pm the night before testing to control for the effects of caffeine already consumed (Marlat & Rosenhow, 1980). Procedure: Each participant attended the human performance laboratory on three occasions. All testing took place between 9.00 am and 12.00 pm with each condition taking place at the same time for each participant to avoid circadian variation. Conditions, separated by 48-72 hours, were randomized and consisted of a caffeine condition where 5 mg/kg of caffeine (Bayer, UK) diluted into 250 ml of artificially sweetened water and a placebo condition where 250 ml of artificially sweetened water were consumed. Solutions were consumed 60 minutes before each exercise trial as plasma caffeine concentration is maximal 1 hour after ingestion of caffeine (Graham, 2001). Solutions were presented to participants in an opaque sports bottle to prevent the researchers administering the solutions or the participants from actually seeing the solutions themselves. | ||
How many outcome-specific endpoints are evaluated? | 1 | ||
What is the (or one of the) endpoint(s) evaluated? (Each endpoint listed separately) | Peak heart rate. | ||
List additional health endpoints (separately). 2 | |||
List additional health endpoints (separately).3 | |||
List additional health endpoints (separately).4 | |||
List additional health endpoints (separately).5 | |||
List additional health endpoints (separately).6 | |||
Clinical, physiological, other | Physiological | ||
What is the study design? | Controlled Trial | ||
Randomized or Non-Randomized? | RCT | ||
What were the diagnostics or methods used to measure the outcome? | Objective | ||
Optional: Name of Method or short description | Not provided. | ||
Caffeine (general) | Caffeine (general) | ||
Coffee, Chocolate, energy drink, gum, medicine/supplement, soda, tea, other? | |||
Measured or self reported? | Measured | ||
Children, adolescents, adults, or pregnant included? | Adults | ||
What was the reference, comparison, or control group(s)? (e.g. high vs low consumption, number of cups, etc.) | 5 mg/kg of caffeine (Bayer, UK) diluted into 250 ml of artificially sweetened water and a placebo condition where 250 ml of artificially sweetened water were consumed + exercise | ||
What were the listed confounders or modifying factors as stated by the authors? (e.g. multi-variable components of models. Copy from methods) | None relevant to heart rate. | ||
What conflicts of interest were reported? | Not discussed. | ||
Refid | 23834545 | ||
What were the sources of funding? | Nor discussed. |
Results & Comparisons
No Results found.